248 related articles for article (PubMed ID: 24565770)
21. Evaluation of asthma control using Global Initiative for Asthma criteria and the Asthma Control Test in Uganda.
Serugendo AN; Kirenga BJ; Hawkes M; Nakiyingi L; Worodria W; Okot-Nwang M
Int J Tuberc Lung Dis; 2014 Mar; 18(3):371-6. PubMed ID: 24670578
[TBL] [Abstract][Full Text] [Related]
22. Smoking as a predictor for loosing control of treated bronchial asthma.
Mihăicuţă S; Ursoniu S; Dumitriu D; Frenţ S; Firă-Mladinescu O; Tudorache V
Pneumologia; 2009; 58(3):186-9. PubMed ID: 19817317
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled trial of a simple emergency department intervention to improve the rate of primary care follow-up for patients with acute asthma exacerbations.
Baren JM; Shofer FS; Ivey B; Reinhard S; DeGeus J; Stahmer SA; Panettieri R; Hollander JE
Ann Emerg Med; 2001 Aug; 38(2):115-22. PubMed ID: 11468604
[TBL] [Abstract][Full Text] [Related]
24. The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States.
Colice GL; Ostrom NK; Geller DE; Anolik R; Blaiss M; Marcus P; Schwartz J; Nathan RA
Ann Allergy Asthma Immunol; 2012 Mar; 108(3):157-62. PubMed ID: 22374197
[TBL] [Abstract][Full Text] [Related]
25. Scheduled asthma management in general practice generally improve asthma control in those who attend.
Backer V; Bornemann M; Knudsen D; Ommen H
Respir Med; 2012 May; 106(5):635-41. PubMed ID: 22349066
[TBL] [Abstract][Full Text] [Related]
26. Real-time asthma outreach reduces excessive short-acting β2-agonist use: a randomized study.
Zeiger RS; Schatz M; Li Q; Solari PG; Zazzali JL; Chen W
J Allergy Clin Immunol Pract; 2014; 2(4):445-456, 456.e1-5. PubMed ID: 25017534
[TBL] [Abstract][Full Text] [Related]
27. Control of persistent asthma in Spain: associated factors.
Díez Jde M; Barcina C; Muñoz M; Leal M
J Asthma; 2008 Nov; 45(9):740-6. PubMed ID: 18972288
[TBL] [Abstract][Full Text] [Related]
28. Associations of patient outcomes with level of asthma control.
Gold LS; Smith N; Allen-Ramey FC; Nathan RA; Sullivan SD
Ann Allergy Asthma Immunol; 2012 Oct; 109(4):260-265.e2. PubMed ID: 23010232
[TBL] [Abstract][Full Text] [Related]
29. Control of asthma in the Maghreb: results of the AIRMAG study.
Benkheder A; Bouacha H; Nafti S; Taright S; El Ftouh M; Yassine N; Fakhfakh H; Ali-Khoudja M; Texier N; El Hasnaoui A
Respir Med; 2009 Dec; 103 Suppl 2():S12-20. PubMed ID: 20122624
[TBL] [Abstract][Full Text] [Related]
30. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma.
Dolan CM; Fraher KE; Bleecker ER; Borish L; Chipps B; Hayden ML; Weiss S; Zheng B; Johnson C; Wenzel S;
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):32-9. PubMed ID: 14756462
[TBL] [Abstract][Full Text] [Related]
31. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community.
Armour C; Bosnic-Anticevich S; Brillant M; Burton D; Emmerton L; Krass I; Saini B; Smith L; Stewart K
Thorax; 2007 Jun; 62(6):496-502. PubMed ID: 17251316
[TBL] [Abstract][Full Text] [Related]
32. Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma.
Tomita K; Sano H; Iwanaga T; Ishihara K; Ichinose M; Kawase I; Kimura H; Hirata K; Fujimura M; Mishima M; Tohda Y
J Asthma; 2012 Apr; 49(3):253-9. PubMed ID: 22376075
[TBL] [Abstract][Full Text] [Related]
33. Ratio of controller to total asthma medications: determinants of the measure.
Broder MS; Gutierrez B; Chang E; Meddis D; Schatz M
Am J Manag Care; 2010 Mar; 16(3):170-8. PubMed ID: 20225912
[TBL] [Abstract][Full Text] [Related]
34. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
35. Overall asthma control: the relationship between current control and future risk.
Bateman ED; Reddel HK; Eriksson G; Peterson S; Ostlund O; Sears MR; Jenkins C; Humbert M; Buhl R; Harrison TW; Quirce S; O'Byrne PM
J Allergy Clin Immunol; 2010 Mar; 125(3):600-8, 608.e1-608.e6. PubMed ID: 20153029
[TBL] [Abstract][Full Text] [Related]
36. Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?
Aubier M; Haughney J; Selroos O; van Schayck OC; Ekström T; Ostinelli J; Buhl R
Ther Adv Respir Dis; 2011 Oct; 5(5):289-98. PubMed ID: 21586508
[TBL] [Abstract][Full Text] [Related]
37. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes.
Schatz M; Zeiger RS; Vollmer WM; Mosen D; Mendoza G; Apter AJ; Stibolt TB; Leong A; Johnson MS; Cook EF
Chest; 2006 Jul; 130(1):43-50. PubMed ID: 16840381
[TBL] [Abstract][Full Text] [Related]
38. Association of asthma control with health care utilization: a prospective evaluation.
Vollmer WM; Markson LE; O'Connor E; Frazier EA; Berger M; Buist AS
Am J Respir Crit Care Med; 2002 Jan; 165(2):195-9. PubMed ID: 11790654
[TBL] [Abstract][Full Text] [Related]
39. Predictive Properties of the Asthma Control Test and Its Component Questions for Severe Asthma Exacerbations.
Cajigal S; Wells KE; Peterson EL; Ahmedani BK; Yang JJ; Kumar R; Burchard EG; Williams LK
J Allergy Clin Immunol Pract; 2017; 5(1):121-127.e2. PubMed ID: 27544712
[TBL] [Abstract][Full Text] [Related]
40. Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States.
Silver HS; Blanchette CM; Kamble S; Petersen H; Letter M; Meddis D; Gutierrez B
J Asthma; 2010 Aug; 47(6):660-6. PubMed ID: 20615167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
